Pfizer Breast Cancer Drug Helps Revive Discarded Strategy

Pfizer Inc., Eli Lilly & Co. and Novartis AG have dug an idea out of the pharmaceutical dustbin to create new medicines that are showing blockbuster potential against hard-to-treat forms of breast cancer.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.